DOCSLIB.ORG

Skin and Soft Tissue Infections Ohsuerin Bonura, MD, MCR Oregon Health & Science University Objectives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Skin and Soft Tissue Infections Ohsuerin Bonura, MD, MCR Oregon Health & Science University Objectives Difficult Skin and Soft tissue Infections OHSUErin Bonura, MD, MCR Oregon Health & Science University Objectives • Compare and contrast the epidemiology and clinical presentation of common skin and soft tissue diseases • State the management for skin and soft tissue infections OHSU• Differentiate true infection from infectious disease mimics of the skin Casey Casey is a 2 year old boy who presents with this rash. What is the best treatment? A. Soap and Water B. Ibuprofen, it will self OHSUresolve C. Dicloxacillin D. Mupirocin OHSUImpetigo Impetigo Epidemiology and Treatment OHSU Ellen Ellen is a 54 year old morbidly obese woman with DM, HTN and venous stasis who presented with a painful left leg and fever. She has had 3 episodes in the last 6 months. What do you recommend? A. Cefazolin followed by oral amoxicillin prophylaxis B. Vancomycin – this is likely OHSUMRSA C. Amoxicillin – this is likely erysipelas D. Clindamycin to cover staph and strep cellulitis Impetigo OHSUErysipelas Erysipelas Risk: lymphedema, stasis, obesity, paresis, DM, ETOH OHSURecurrence rate: 30% in 3 yrs Treatment: Penicillin Impetigo Erysipelas OHSUCellulitis Cellulitis • DEEPER than erysipelas • Microbiology: – 6-48hrs post op: think GAS… too early for staph (days in the making)! – Periorbital – Staph, Strep pneumoniae, GAS OHSU– Post Varicella - GAS – Skin popping – Staph + almost anything! Framework for Skin and Soft Tissue Infections (SSTIs) NONPurulent Purulent Necrotizing/Cellulitis/Erysipelas Furuncle/Carbuncle/Abscess Severe Moderate Mild Severe Moderate Mild I&D I&D I&D I&D IV Rx Oral Rx C&S C&S C&S C&S Vanc + Pip-tazo OHSUEmpiric IV Empiric MRSA Oral MRSA TMP/SMX Doxy What Are Your “Go-To” Oral Options For Non-Purulent SSTI? Amoxicillin Doxycycline OHSUCephalexin Doxycycline Trimethoprim-Sulfamethoxazole OHSU Miller LG, et al. Clindamycin versus Trimethoprim-Sulfamethoxazole for uncomplicated skin infections. NEJM.2015;372(12):1093-1103 Cure rate: Clinda vs TMP/SMX vs Placebo Clindamycin TMP-SMX Placebo All - ITT 83.1 81.7 68.9 - Evaluated 92.9 92.7 80.5 Children - ITT 89.1 82.4 68.5 - Evaluated 97.8 92.6 82.4 Adults - ITT 79.4 81.4 69.0 - Evaluated 89.7 92.7 79.5 No S. aureus - ITT 83.8 91.9 83.1 OHSU- Evaluated 90.5 90.8 90.8 Daum RS., et al. A placebo-controlled trial of antibiotics for smaller skin abscesses. NEJM. 2017;376(26):2545-2555 What About Prophylaxis? Erythromycin x 18 m No prophylaxis Complete Prevention 16 Relapse ------ 8 (One Relapse) (7) OHSU(Two Relapses) (1) Kremer M, et al. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect. 1991;22(1):37-40. More Data on Prophylaxis OHSU Sjoblom AC et al. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993;21:390–3. When Should We Give Prophylaxis? • 1st: Identify and treat predisposing conditions • If still 3-4 episodes per year • Penicillin or erythromycin BID x 4-52 weeks or IM benzathine PCN every 2-4 weeks • Continue as long as predisposing factors OHSUpresent IDSA Practice Guidelines for SSTI. 2014 Jessie is a 32 yo radio host at NPR who volunteers at the local animal shelter. She was bitten by a cat 2 hours ago and comes in for evaluation. She has 2 puncture marks on her L thenar eminence without spreading erythema. Her last tetanus shot was 3 years ago. What should you do? A. Treat with amoxicillin B. Treat with amoxicillin-clavulanate OHSUC. Send her to the ED for IV antibiotics D. Wash the wound, give a tetanus booster, and do not give antibiotics Cats…. OHSU Messer Biting Things 19 Dogs…. OHSU Messer Biting Things 20 Microbiology of cat and dog bites Dog Bites Cat Bites • Pasteurella spp (50%) • Pasteurella spp (75%) • Streptococci (46%) • Streptococci (46%) • Staphylococci (46%) • Staphylococci (35%) • Neisseria spp (32%) • Neisseria spp (35%) • Fusobacterium spp (32%) • Fusobacterium spp (33%) OHSU• Capnocyphaga canimorsus • Bartonella henslae Clin Microbiol Rev. 2011 Apr; 24(2): 231–246. Messer Biting Things 21 Evaluation and management of animal bites • Animal – ownership - provocation, History • Vaccination history • Pt History • Expose area • Type of Wound • Function Exam OHSU• LAD • No culture if no infection >24hs Further • Xray if suspicion for fracture, osteo, FB • Copious I&D Work up • Possibly closure Who do you treat? OHSU When to give toxoid and Tetanus Ig Previous # Clean and Minor Wounds All other Wounds Toxoid Doses (dirt, feces, soil, saliva, puncture, avulsions, crushing, burns, frostbite) Tetanus toxoid Tetanus Ig Tetanus toxoid Tetanus Ig vaccine vaccine <3 doses YES NO YES YES OHSU>3 doses If >10yrs ago NO If > 5yrs ago NO Jane is a 62 yo female with lupus on prednisone 10 and azathioprine who presents with recurrent MRSA abscesses. She has undergone numerous I&Ds and rounds of antibiotics. What do you suggest? A. Decolonize with mupirocin and chlorhexidine B. Decrease her immunosuppression OHSUC. Start suppressive antibiotics D. Treat what comes Stringent Decolonization in a German Village (2002-2005) Personal Items & Linens Body Wash • TID x 5 • Chlorhexidine • Comb • Alcohol days • Skin & Hair • Razor based • Jewlery Mupirocin Gargling • Clothes Tub/Shower OHSU• Sheets Wiese-Posselt M, et al. Clin Infect Dis. 2007;44(11):e88-95 Stringent Decolonization in a German Village (2002-2005) OHSU Wiese-Posselt M, et al. Clin Infect Dis. 2007;44(11):e88-95 Eradication of Carriage versus Recurrence of Disease 183 Peds Subjects OHSUCases Decolonization Case Household Fritz SA, et al. Clin Infect Dis. 2012;54(6):743-51 Eradication versus Recurrence Recurrence Rate At 12 months • 72% in case OHSU• 52% in household (P=0.02) Fritz SA, et al. Clin Infect Dis. 2012;54(6):743-51 Management of Recurrent Abscesses • If occur since childhood, evaluate for defect • If at the same site, evaluate for local cause • Drain and culture • Treat 5-10 days OHSU• *Consider* decolonization Practice Guidelines SSSI. CID. 2014 Al, is a 65 yo diabetic man with a HbA1c of 10 on insulin. He presents to the ED with a rash over his L buttock that is warm, and extremely tender. He states there was a pimple that popped and over the next few hours this developed. He has a fever to 101 with other vitals stable. On exam, he has a warm, erythematous area of 20x16 cm which is more tender than you would expect on exam and does not have clear demarcations. There is no crepitus. • Pair up with the person next to you. OHSU• What is the working diagnosis? • What is your management? • Look like cellulitis • Spreads along fascia • Pain out of proportion • Rapidly progressive OHSU• Surgical emergency Type I Type II Type III Conventional Name Fournier’s (GU) Streptococcal Gas Gangrene gangrene Pathogens Polymicrobial Group A Strep Clostridium pyogenes S. aureus Host Diabetics Varicella Traumatic injury Immunocompromised Peripheral Vascular Disease OHSURecent Surgery OHSU Empiric Antibiotic Choice Suspected Option 1 Option 2 Option 3 pathogens Mixed Pip-tazo + vanc Carbapenem Cefotaxime+ metro or clinda Streptococcal Penicillin + Clinda Staph aureus Nafcillin Vancomycin Clindamycin* Clostridial Penicillin + Clinda *Bacteriostatic; potential cross-resistance and emergence of resistance in OHSUerythromycin resistant strains; inducible resistance in MRSA Clindamycin Data OHSU Stevens DL., et al. International Journal of Antimicrobial Agents 4 (1994) 297-301 Clindamycin data OHSU Stevens, DL., et al. Clinical Infectious Diseases, Vol. 20, Supplement 2. Proceedings of the 1994 Meeting of the Anaerobe Society of the Americas (Jun., 1995), pp. S154-S157 OHSU New Case of PG Sarah is a 32 yo female with a history of IBS who presents to you with this wound. She states it started as a pustule that OHSUprogressed. She has tried multiple course of antibiotics but nothing works. Case of the Non-healing Wound What is the cause? 1. MRSA 2. Mycobacteria marinum 3. Vascular disease 4. OHSUSweet’s Syndrome 5. Pyoderma gangrenosum OHSU Instructor Name Session Title and Date Delivered 41 OHSUThank you for your participation!! I would like to acknowledge Dr. Bill Messer & Dr. Melissa Nyendak OHSU When to give toxoid and Tetanus Ig Previous # Clean and Minor Wounds All other Wounds Toxoid Doses (dirt, feces, soil, saliva, puncture, avulsions, crushing, burns, frostbite) Tetanus toxoid Tetanus Ig Tetanus toxoid Tetanus Ig vaccine vaccine <3 doses YES NO YES YES OHSU>3 doses If >10yrs ago NO If > 5yrs ago NO Sweet Syndrome OHSU Instructor Name Session Title and Date Delivered 45 Sweet Syndrome • Inflammatory • 87% Heme • Many! Bowel Disease • URI, GI • Pregnancy OHSUClassical Malignancy Drug Instructor Name Session Title and Date Delivered 46 Neutrophilic Infiltration OHSU Instructor Name Session Title and Date Delivered 47.
Load more

Recommended publications
  • Oral Lichen Planus: a Case Report and Review of Literature
    Journal of the American Osteopathic College of Dermatology Volume 10, Number 1 SPONSORS: ',/"!,0!4(/,/'9,!"/2!4/29s-%$)#)3 March 2008 34)%&%,,!"/2!4/2)%3s#/,,!'%.%8 www.aocd.org Journal of the American Osteopathic College of Dermatology 2007-2008 Officers President: Jay Gottlieb, DO President Elect: Donald Tillman, DO Journal of the First Vice President: Marc Epstein, DO Second Vice President: Leslie Kramer, DO Third Vice President: Bradley Glick, DO American Secretary-Treasurer: Jere Mammino, DO (2007-2010) Immediate Past President: Bill Way, DO Trustees: James Towry, DO (2006-2008) Osteopathic Mark Kuriata, DO (2007-2010) Karen Neubauer, DO (2006-2008) College of David Grice, DO (2007-2010) Dermatology Sponsors: Global Pathology Laboratory Stiefel Laboratories Editors +BZ4(PUUMJFC %0 '0$00 Medicis 4UBOMFZ&4LPQJU %0 '"0$% CollaGenex +BNFT2%FM3PTTP %0 '"0$% Editorial Review Board 3POBME.JMMFS %0 JAOCD &VHFOF$POUF %0 Founding Sponsor &WBOHFMPT1PVMPT .% A0$%t&*MMJOPJTt,JSLTWJMMF .0 4UFQIFO1VSDFMM %0 t'"9 %BSSFM3JHFM .% wwwBPDEPSg 3PCFSU4DIXBS[F %0 COPYRIGHT AND PERMISSION: written permission must "OESFX)BOMZ .% be obtained from the Journal of the American Osteopathic College of Dermatology for copying or reprinting text of .JDIBFM4DPUU %0 more than half page, tables or figurFT Permissions are $JOEZ)PGGNBO %0 normally granted contingent upon similar permission from $IBSMFT)VHIFT %0 the author(s), inclusion of acknowledgement of the original source, and a payment of per page, table or figure of #JMM8BZ %0 reproduced matFSJBMPermission fees
    [Show full text]
  • Naeglaria and Brain Infections
    Can bacteria shrink tumors? Cancer Therapy: The Microbial Approach n this age of advanced injected live Streptococcus medical science and into cancer patients but after I technology, we still the recipients unfortunately continue to hunt for died from subsequent innovative cancer therapies infections, Coley decided to that prove effective and safe. use heat killed bacteria. He Treatments that successfully made a mixture of two heat- eradicate tumors while at the killed bacterial species, By Alan Barajas same time cause as little Streptococcus pyogenes and damage as possible to normal Serratia marcescens. This Alani Barajas is a Research and tissue are the ultimate goal, concoction was termed Development Technician at Hardy but are also not easy to find. “Coley’s toxins.” Bacteria Diagnostics. She earned her bachelor's degree in Microbiology at were either injected into Cal Poly, San Luis Obispo. The use of microorganisms in tumors or into the cancer therapy is not a new bloodstream. During her studies at Cal Poly, much idea but it is currently a of her time was spent as part of the undergraduate research team for the buzzing topic in cancer Cal Poly Dairy Products Technology therapy research. Center studying spore-forming bacteria in dairy products. In the late 1800s, German Currently she is working on new physicians W. Busch and F. chromogenic media formulations for Fehleisen both individually Hardy Diagnostics, both in the observed that certain cancers prepared and powdered forms. began to regress when patients acquired accidental erysipelas (cellulitis) caused by Streptococcus pyogenes. William Coley was the first to use New York surgeon William bacterial injections to treat cancer www.HardyDiagnostics.com patients.
    [Show full text]
  • Hawaii State Department of Health Tetanus Factsheet
    TETANUS ABOUT THIS DISEASE Tetanus is an infection caused by a bacterium called Clostridium tetani. Spores of tetanus bacteria are everywhere in the environment, including soil, dust, and manure. These spores develop into bacteria when they enter the body through breaks in the skin, usually through injuries from contaminated objects. Clostridium tetani produce a toxin (poison) that causes painful muscle contractions. Tetanus is often called “lockjaw” because the first sign is most commonly spasms of the jaw muscles. Tetanus can lead to serious health problems, including being unable to open the mouth and having trouble swallowing and breathing, possibly leading to death (10% to 20% of cases). Tetanus is uncommon in the United States, with an average of 30 reported cases each year. Nearly all cases of tetanus in the U.S. are among people who have never received a tetanus vaccine, or adults who don’t stay up to date on their 10-year booster shots. SIGNS AND SYMPTOMS Symptoms of tetanus include: • Jaw cramping • Sudden, involuntary muscle tightening (muscle spasms) – often in the stomach • Painful muscle stiffness all over the body • Trouble swallowing • Jerking or staring (seizures) • Headache • Fever and sweating • Changes in blood pressure and a fast heart rate. Serious health problems that can happen because of tetanus include: • Laryngospasm (uncontrolled/involuntary tightening of the vocal cords) • Fractures (broken bones) • Hospital-acquired infections (Infections caught by a patient during a hospital stay) • Pulmonary embolism (blockage of the main artery of the lung or one of its branches by a blood clot that has travelled from elsewhere in the body through the bloodstream) • Aspiration pneumonia (lung infection that develops by breathing in foreign materials) • Breathing difficulty, possibly leading to death (1 to 2 in 10 cases are fatal) TRANSMISSION Tetanus is different from other vaccine-preventable diseases because it does not spread from person to person.
    [Show full text]
  • Safety and Immunogenicity of Capsular Polysaccharide–Tetanus Toxoid Conjugate Vaccines for Group B Streptococcal Types Ia and Ib
    142 Safety and Immunogenicity of Capsular Polysaccharide±Tetanus Toxoid Conjugate Vaccines for Group B Streptococcal Types Ia and Ib Carol J. Baker, Lawrence C. Paoletti, Section of Infectious Diseases, Departments of Pediatrics and of Michael R. Wessels, Hilde-Kari Guttormsen, Microbiology and Immunology, Baylor College of Medicine, Houston, Marcia A. Rench, Melissa E. Hickman, Texas; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Department of Microbiology and Molecular and Dennis L. Kasper Genetics, Harvard Medical School, Boston, Massachusetts About 40% of invasive group B streptococcal (GBS) isolates are capsular polysaccharide Downloaded from https://academic.oup.com/jid/article/179/1/142/877598 by guest on 01 October 2021 (CPS) types Ia or Ib. Because infant and maternal GBS infections may be preventable by maternal vaccination, individual GBS CPS have been coupled to tetanus toxoid (TT) to prepare vaccines with enhanced immunogenicity. Immunogenicity in rabbits and protective capacity in mice of a series of type Ia- and Ib-TT conjugates increased with the degree of polysaccharide-to-protein cross-linking. In total, 190 healthy, nonpregnant women aged 18±40 years were randomized in four trials to receive Ia- or Ib-TT conjugate (dose range, 3.75±63 mg of CPS component), uncoupled Ia or Ib CPS, or saline. All vaccines were well-tolerated. CPS-speci®c IgG serum concentrations peaked 4±8 weeks after vaccination and were signif- icantly higher in recipients of conjugated than of uncoupled CPS. Immune responses to the conjugates were dose-dependent and correlated in vitro with opsonophagocytosis. These re- sults support inclusion of Ia- and Ib-TT conjugates when formulating a multivalent GBS vaccine.
    [Show full text]
  • Communicable Disease Exclusion Guidelines for Schools and Child Care Settings
    Deschutes County Health Services COMMUNICABLE DISEASE EXCLUSION GUIDELINES FOR SCHOOLS AND CHILD CARE SETTINGS Symptoms requiring exclusion of a child from school or childcare setting until either diagnosed and cleared by a licensed health care provider or recovery. FEVER: ANY fever greater than 100.5 F., may return when temperature decreases without use of fever-reducing medicine. VOMITTING: > 2 in the preceding 24 hours, unless determined to be from non-communicable conditions. May return when resolved. DIARRHEA: 3 or more watery or loose stools in 24 hours. May return when resolved for 24 hours. STIFF NECK: or headache with accompanying fever. May return after resolution of symptoms or diagnosis made and clearance given. RASHES: ANY new onset of rash if accompanied by fever; may return after rash resolves or if clearance given by health care providers. SKIN LESIONS: Drainage that cannot be contained within a bandage. JAUNDICE: Yellowing of eyes or skin. May return after diagnosis from physician and clearance given. BEHAVIOR CHANGE: Such as new onset of irritability, lethargy or somnolence. COUGH /SOB: Persistent cough with or without fever, serious sustained coughing, shortness of breath, or difficulty breathing. SYMPTOMS or complaints that prevent the student from active participation in usual school activities, or student requiring more care than the school staff can safely provide. Inform local county health department, (LHD), of all diseases listed as reportable. The local county health department should be consulted regarding any written communication that may be developed to inform parents/guardians about disease outbreaks, risk to students, families, and staff and/or control measures specific to an outbreak.
    [Show full text]
  • Diagnostic Code Descriptions (ICD9)
    INFECTIONS AND PARASITIC DISEASES INTESTINAL AND INFECTIOUS DISEASES (001 – 009.3) 001 CHOLERA 001.0 DUE TO VIBRIO CHOLERAE 001.1 DUE TO VIBRIO CHOLERAE EL TOR 001.9 UNSPECIFIED 002 TYPHOID AND PARATYPHOID FEVERS 002.0 TYPHOID FEVER 002.1 PARATYPHOID FEVER 'A' 002.2 PARATYPHOID FEVER 'B' 002.3 PARATYPHOID FEVER 'C' 002.9 PARATYPHOID FEVER, UNSPECIFIED 003 OTHER SALMONELLA INFECTIONS 003.0 SALMONELLA GASTROENTERITIS 003.1 SALMONELLA SEPTICAEMIA 003.2 LOCALIZED SALMONELLA INFECTIONS 003.8 OTHER 003.9 UNSPECIFIED 004 SHIGELLOSIS 004.0 SHIGELLA DYSENTERIAE 004.1 SHIGELLA FLEXNERI 004.2 SHIGELLA BOYDII 004.3 SHIGELLA SONNEI 004.8 OTHER 004.9 UNSPECIFIED 005 OTHER FOOD POISONING (BACTERIAL) 005.0 STAPHYLOCOCCAL FOOD POISONING 005.1 BOTULISM 005.2 FOOD POISONING DUE TO CLOSTRIDIUM PERFRINGENS (CL.WELCHII) 005.3 FOOD POISONING DUE TO OTHER CLOSTRIDIA 005.4 FOOD POISONING DUE TO VIBRIO PARAHAEMOLYTICUS 005.8 OTHER BACTERIAL FOOD POISONING 005.9 FOOD POISONING, UNSPECIFIED 006 AMOEBIASIS 006.0 ACUTE AMOEBIC DYSENTERY WITHOUT MENTION OF ABSCESS 006.1 CHRONIC INTESTINAL AMOEBIASIS WITHOUT MENTION OF ABSCESS 006.2 AMOEBIC NONDYSENTERIC COLITIS 006.3 AMOEBIC LIVER ABSCESS 006.4 AMOEBIC LUNG ABSCESS 006.5 AMOEBIC BRAIN ABSCESS 006.6 AMOEBIC SKIN ULCERATION 006.8 AMOEBIC INFECTION OF OTHER SITES 006.9 AMOEBIASIS, UNSPECIFIED 007 OTHER PROTOZOAL INTESTINAL DISEASES 007.0 BALANTIDIASIS 007.1 GIARDIASIS 007.2 COCCIDIOSIS 007.3 INTESTINAL TRICHOMONIASIS 007.8 OTHER PROTOZOAL INTESTINAL DISEASES 007.9 UNSPECIFIED 008 INTESTINAL INFECTIONS DUE TO OTHER ORGANISMS
    [Show full text]
  • Boils and Skin Infections Are Usually Caused by Bacteria
    Communicable Diseases Factsheet Boils and skin infections are usually caused by bacteria. Avoid sharing items and wash hands thoroughly, especially after touching skin Boils and skin infections infections. Last updated: March 2017 What are boils? A boil (sometimes known as a furuncle) is an infection of the skin, often around a hair follicle. It is usually caused by Staphylococcus aureus bacteria (commonly known as golden staph). Many healthy people carry these bacteria on their skin or in their nose, but do not have any symptoms. Boils occur when bacteria get through broken skin and cause tender, swollen, pimple-like sores, which are full of pus. Boils usually get better on their own, but severe or recurring cases may require medical treatment and support. Staph bacteria may also cause other skin infections, including impetigo. Impetigo, commonly known as school sores (as they affect school-age children), are small blisters or flat crusty sores on the skin. See the Impetigo factsheet at http://www.health.nsw.gov.au/Infectious/factsheets/Pages/impetigo.aspx for specific information on Impetigo. How are they diagnosed? Most skin infections are diagnosed on the basis of their appearance and the presence of any related symptoms (such as fever). Your doctor may take swabs or samples from boils, wounds, or other sites of infection to identify the bacteria responsible. Some infections may be caused by bacteria that are resistant to some antibiotics. See the MRSA in the community factsheet for detailed information on infections caused by antibiotic
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Reportable Disease Surveillance in Virginia, 2013
    Reportable Disease Surveillance in Virginia, 2013 Marissa J. Levine, MD, MPH State Health Commissioner Report Production Team: Division of Surveillance and Investigation, Division of Disease Prevention, Division of Environmental Epidemiology, and Division of Immunization Virginia Department of Health Post Office Box 2448 Richmond, Virginia 23218 www.vdh.virginia.gov ACKNOWLEDGEMENT In addition to the employees of the work units listed below, the Office of Epidemiology would like to acknowledge the contributions of all those engaged in disease surveillance and control activities across the state throughout the year. We appreciate the commitment to public health of all epidemiology staff in local and district health departments and the Regional and Central Offices, as well as the conscientious work of nurses, environmental health specialists, infection preventionists, physicians, laboratory staff, and administrators. These persons report or manage disease surveillance data on an ongoing basis and diligently strive to control morbidity in Virginia. This report would not be possible without the efforts of all those who collect and follow up on morbidity reports. Divisions in the Virginia Department of Health Office of Epidemiology Disease Prevention Telephone: 804-864-7964 Environmental Epidemiology Telephone: 804-864-8182 Immunization Telephone: 804-864-8055 Surveillance and Investigation Telephone: 804-864-8141 TABLE OF CONTENTS INTRODUCTION Introduction ......................................................................................................................................1
    [Show full text]
  • Early History of Infectious Disease 
    © Jones and Bartlett Publishers. NOT FOR SALE OR DISTRIBUTION CHAPTER ONE EARLY HISTORY OF INFECTIOUS 1 DISEASE Kenrad E. Nelson, Carolyn F. Williams Epidemics of infectious diseases have been documented throughout history. In ancient Greece and Egypt accounts describe epidemics of smallpox, leprosy, tuberculosis, meningococcal infections, and diphtheria.1 The morbidity and mortality of infectious diseases profoundly shaped politics, commerce, and culture. In epidemics, none were spared. Smallpox likely disfigured and killed Ramses V in 1157 BCE, although his mummy has a significant head wound as well.2 At times political upheavals exasperated the spread of disease. The Spartan wars caused massive dislocation of Greeks into Athens triggering the Athens epidemic of 430–427 BCE that killed up to one half of the population of ancient Athens.3 Thucydides’ vivid descriptions of this epidemic make clear its political and cultural impact, as well as the clinical details of the epidemic.4 Several modern epidemiologists have hypothesized on the causative agent. Langmuir et al.,5 favor a combined influenza and toxin-producing staphylococcus epidemic, while Morrens and Chu suggest Rift Valley Fever.6 A third researcher, Holladay believes the agent no longer exists.7 From the earliest times, man has sought to understand the natural forces and risk factors affecting the patterns of illness and death in society. These theories have evolved as our understanding of the natural world has advanced, sometimes slowly, sometimes, when there are profound break- throughs, with incredible speed. Remarkably, advances in knowledge and changes in theory have not always proceeded in synchrony. Although wrong theories or knowledge have hindered advances in understanding, there are also examples of great creativity when scientists have successfully pursued their theories beyond the knowledge of the time.
    [Show full text]
  • Viability of Methicillin-Resistant Staphylococcus Aureus on Artificial Turf Under
    Viability of Methicillin-Resistant Staphylococcus aureus on Artificial Turf Under Outdoor and Laboratory Environmental Conditions A thesis presented to the faculty of the College of Health Sciences and Professions of Ohio University In partial fulfillment of the requirements for the degree Master of Science Ashley N. Hardbarger June 2012 © 2012 Ashley N. Hardbarger. All Rights Reserved. 2 This thesis titled Viability of Methicillin-Resistant Staphylococcus aureus on Artificial Turf Under Outdoor and Laboratory Environmental Conditions by ASHLEY N. HARDBARGER has been approved for the School of Applied Health Sciences and Wellness and the College of Health Sciences and Professions by Andrew Krause Assistant Professor of Applied Health Sciences and Wellness Randy Leite Dean, College of Health Sciences and Professions 3 ABSTRACT HARDBARGER, ASHLEY N., M.S., June 2012, Athletic Training Viability of Methicillin-Resistant Staphylococcus Aureus on Artificial Turf Under Outdoor and Laboratory Environmental Conditions Director of Thesis: Andrew Krause Methicillin-resistant Staphylococcus aureus has survived on artificial turf in a laboratory setting when provided a nutrient source. There is limited evidence on the viability of MRSA in outdoor environmental conditions. This study compared the survival of MRSA in a laboratory environment to an outdoor environment over seven days. Artificial turf was inoculated with MRSA strain USA300 and exposed to laboratory and outdoor environmental settings. Samples were collected daily. MRSA survival was determined by growth on CHROMagar plates. Results indicated a difference in the mean survival time of MRSA between a laboratory environment (7.00 ± 0.00 days) and an outdoor environment (4.67 ± 2.52). Conditions including surface temperature, ambient temperature, relative humidity, precipitation and solar radiation may have affected MRSA survival.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]